398 related articles for article (PubMed ID: 19650170)
1. Brain metastases as late breast cancer relapse. Single institution experience and review of the literature.
Tomasevic Z; Radosevic-Jelic Lj; Jovanovic D; Milovanovic Z; Tomasevic ZM; Jelic S; Borojevic N
J BUON; 2009; 14(2):225-8. PubMed ID: 19650170
[TBL] [Abstract][Full Text] [Related]
2. HER2 status in patients with breast carcinoma is not modified selectively by preoperative chemotherapy and is stable during the metastatic process.
Vincent-Salomon A; Jouve M; Genin P; Fréneaux P; Sigal-Zafrani B; Caly M; Beuzeboc P; Pouillart P; Sastre-Garau X
Cancer; 2002 Apr; 94(8):2169-73. PubMed ID: 12001113
[TBL] [Abstract][Full Text] [Related]
3. Incidence of brain metastases in early stage HER2 3+ breast cancer patients; is there a role for brain CT in asymptomatic patients?
Tomasevic ZI; Rakocevic Z; Tomasevic ZM; Milovanovic Z; Inic M; Kolarevic D; Lukic V; Kovac Z
J BUON; 2012; 17(2):249-53. PubMed ID: 22740201
[TBL] [Abstract][Full Text] [Related]
4. [Prevalence of elevated serum CA 15-3 at time of metastatic relapse of breast cancer and correlation with hormone receptor status].
Bensouda Y; André F; Boulet T; Al-Ghuzlan A; Conforti R; Troalen F; Bourgier C; Errihani H; Spielmann M; Delaloge S
Bull Cancer; 2009 Oct; 96(10):923-8. PubMed ID: 19696005
[TBL] [Abstract][Full Text] [Related]
5. Central nervous system metastases in women after multimodality therapy for high risk breast cancer.
Carey LA; Ewend MG; Metzger R; Sawyer L; Dees EC; Sartor CI; Moore DT; Graham ML
Breast Cancer Res Treat; 2004 Dec; 88(3):273-80. PubMed ID: 15609130
[TBL] [Abstract][Full Text] [Related]
6. Survival in patients with brain metastases from breast cancer: the importance of HER-2 status.
Eichler AF; Kuter I; Ryan P; Schapira L; Younger J; Henson JW
Cancer; 2008 Jun; 112(11):2359-67. PubMed ID: 18361426
[TBL] [Abstract][Full Text] [Related]
7. HER2 significance and treatment outcomes after radiotherapy for brain metastases in breast cancer patients.
Wolstenholme V; Hawkins M; Ashley S; Tait D; Ross G
Breast; 2008 Dec; 17(6):661-5. PubMed ID: 18571923
[TBL] [Abstract][Full Text] [Related]
8. Factors affecting the prognosis of breast cancer patients with brain metastases.
Saip P; Cicin I; Eralp Y; Kucucuk S; Tuzlali S; Karagol H; Aslay I; Topuz E
Breast; 2008 Oct; 17(5):451-8. PubMed ID: 18455400
[TBL] [Abstract][Full Text] [Related]
9. Changes of serum HER2 status during clinical course of metastatic breast cancer patients.
Fehm T; Jäger W; Kraemer S; Sohn C; Solomayer-Meyberg G; Solomayer EF; Kurek R; Wallwiener D; Gebauer G
Anticancer Res; 2004; 24(6):4205-10. PubMed ID: 15739264
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of human epidermal growth factor receptor positivity for the development of brain metastasis after newly diagnosed breast cancer.
Gabos Z; Sinha R; Hanson J; Chauhan N; Hugh J; Mackey JR; Abdulkarim B
J Clin Oncol; 2006 Dec; 24(36):5658-63. PubMed ID: 17102066
[TBL] [Abstract][Full Text] [Related]
11. Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal cytokeratin CK5/6, and overexpress HER2 or EGFR.
Hicks DG; Short SM; Prescott NL; Tarr SM; Coleman KA; Yoder BJ; Crowe JP; Choueiri TK; Dawson AE; Budd GT; Tubbs RR; Casey G; Weil RJ
Am J Surg Pathol; 2006 Sep; 30(9):1097-104. PubMed ID: 16931954
[TBL] [Abstract][Full Text] [Related]
12. Risk factors for brain relapse in HER2-positive metastatic breast cancer patients.
Duchnowska R; Dziadziuszko R; Czartoryska-Arłukowicz B; Radecka B; Szostakiewicz B; Sosińska-Mielcarek K; Karpińska A; Starosławska E; Kubiatowski T; Szczylik C
Breast Cancer Res Treat; 2009 Sep; 117(2):297-303. PubMed ID: 19130219
[TBL] [Abstract][Full Text] [Related]
13. Single nucleotide polymorphisms of the aromatase gene (CYP19A1), HER2/neu status, and prognosis in breast cancer patients.
Fasching PA; Loehberg CR; Strissel PL; Lux MP; Bani MR; Schrauder M; Geiler S; Ringleff K; Oeser S; Weihbrecht S; Schulz-Wendtland R; Hartmann A; Beckmann MW; Strick R
Breast Cancer Res Treat; 2008 Nov; 112(1):89-98. PubMed ID: 18049890
[TBL] [Abstract][Full Text] [Related]
14. Breast cancer risk factors and HER2 over-expression in tumors.
Swede H; Moysich KB; Freudenheim JL; Quirk JT; Muti PC; Hurd TC; Edge SB; Winston JS; Michalek AM
Cancer Detect Prev; 2001; 25(6):511-9. PubMed ID: 12132871
[TBL] [Abstract][Full Text] [Related]
15. Brain metastases in HER2-positive breast cancer: the evolving role of lapatinib.
Tomasello G; Bedard PL; de Azambuja E; Lossignol D; Devriendt D; Piccart-Gebhart MJ
Crit Rev Oncol Hematol; 2010 Aug; 75(2):110-21. PubMed ID: 20004109
[TBL] [Abstract][Full Text] [Related]
16. The effect of early detection of occult brain metastases in HER2-positive breast cancer patients on survival and cause of death.
Niwińska A; Tacikowska M; Murawska M
Int J Radiat Oncol Biol Phys; 2010 Jul; 77(4):1134-9. PubMed ID: 19932944
[TBL] [Abstract][Full Text] [Related]
17. Extracellular domain of HER2: a useful marker for the initial workup and follow-up of HER2-positive breast cancer.
Garoufali A; Kyriakou F; Kountourakis P; Yioti I; Malliou S; Nikaki A; Kardara E; Frangos I; Koumna S; Baziotis N; Scorilas A; Ardavanis A
J BUON; 2008; 13(3):409-13. PubMed ID: 18979558
[TBL] [Abstract][Full Text] [Related]
18. Angiogenesis and c-erbB-2 (HER2/neu) overexpression status in primary breast cancer patients: an analysis of 158 needle core biopsies.
Vameşu S
Rom J Morphol Embryol; 2007; 48(2):121-9. PubMed ID: 17641798
[TBL] [Abstract][Full Text] [Related]
19. Symptomatic bone marrow involvement in breast cancer--clinical presentation, treatment, and prognosis: a single institution review of 22 cases.
Kopp HG; Krauss K; Fehm T; Staebler A; Zahm J; Vogel W; Kanz L; Mayer F
Anticancer Res; 2011 Nov; 31(11):4025-30. PubMed ID: 22110237
[TBL] [Abstract][Full Text] [Related]
20. Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System.
Barnholtz-Sloan JS; Sloan AE; Davis FG; Vigneau FD; Lai P; Sawaya RE
J Clin Oncol; 2004 Jul; 22(14):2865-72. PubMed ID: 15254054
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
